

PREFERRED SPECIALTY MANAGEMENT POLICY

POLICY: Oncology – Dasatinib Preferred Specialty Management Policy

- Sprycel® (dasatinib tablets – Bristol-Myers Squibb, generic)

REVIEW DATE: 10/02/2024; Effective 01/01/2025

OVERVIEW

Dasatinib, a tyrosine kinase inhibitor (TKI), is indicated for the following uses:¹

- **Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL):**
 - In adults with resistance or intolerance to prior therapy.
 - In newly diagnosed pediatric patients ≥ 1 year of age in combination with chemotherapy.
- **Ph+ chronic myeloid leukemia (CML):**
 - Chronic phase in newly diagnosed adults.
 - Chronic phase, accelerated, or myeloid or lymphoid blast phase, in adults with resistance or intolerance to prior therapy including imatinib.
 - Chronic phase, in pediatric patients ≥ 1 year of age.

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of the Preferred Product. For all medications (Preferred and Non-Preferred), the patient is required to meet the standard *Oncology – Dasatinib Prior Authorization Policy* criteria. The program also directs the patient to try the Preferred Product prior to the approval of the Non-Preferred Product. Requests for the Non-Preferred Product will also be reviewed using the exception criteria (below). If the patient meets the standard *Oncology – Dasatinib Prior Authorization Policy* criteria but has not tried a Preferred Product, approval for the Preferred Product will be authorized. All approvals are provided for the duration noted below.

Documentation: Documentation will be required where noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to, chart notes, prescription claims records, and prescription receipts.

Automation: None

Preferred Product: generic dasatinib tablets
Non-Preferred Product: Sprycel

RECOMMENDED EXCEPTION CRITERIA

REFERENCES

1. Sprycel tablets [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; July 2024.